Announcement: Aurelia Bioscience has been acquired by Charnwood Molecular.

Share this

Linos Lazarides joins Charnwood Molecular as Senior Business Development Executive, with responsibilities in Europe.

Linos has previous business development experience in providing medicinal and synthetic chemistry and preclinical integrated drug discovery projects. Prior to that, he worked at GSK and then Selcia Ltd as a medicinal chemist.

The new appointment will enable Charnwood Molecular to deliver its ambitious growth plan, promoting the company as a trusted partner in innovative chemistry, working alongside expert CRO providers in other drug discovery disciplines, to deliver drug candidates to clinical stages in accelerated timelines.

“We are delighted that Linos has joined us at such an exciting time for the company,” said Dr Robin Wilkes, Director of Business Development. “He brings exceptional experience and relationships in our sector and his involvement will enable better coverage of a key client territory for Charnwood Molecular”, he added.

Charnwood Molecular has seen significant expansion of its global client base in recent years and the expansion of the business development team will further support continued growth in our wide range of contract research services, from medicinal chemistry, chemical development and early process research to providing other bespoke synthetic chemistry support for our international clients.